The performance of companies tied to Sildenafil's legacy presents a challenging investment picture . While the initial boom generated substantial gains, generic copies have significantly diminished sales . Investing in related pharmaceutical firms now requires a thorough assessment of intellectual property protection , evolving healthcare trends ,